Market Overview

UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, $25 PT; Risk-Mitigated Opportunity

Share:
Related AMRN
Watch These 8 Huge Call Purchases In Wednesday Trade
Benzinga's Option Alert Recap From March 21

Aegis Capital said on Monday that it initiated coverage on Amarin Corporation (NASDAQ: AMRN) with a Buy rating and a price target of $25.

Aegis Capital said, "In our view, Amarin constitutes one of the most risk-mitigated opportunities in the biotechnology sector, as the firm's lead product candidate has already successfully demonstrated safety and efficacy in two randomized, placebo-controlled Phase 3 clinical trials. These studies were conducted under Special Protocol Assessments (SPAs) from the U.S. FDA."

Amarin Corporation closed at $15.12 on Friday.

Latest Ratings for AMRN

DateFirmActionFromTo
Oct 2016CitigroupInitiates Coverage OnBuy
Oct 2016Cantor FitzgeraldInitiates Coverage onBuy
Oct 2016Cantor FitzgeraldInitiates Coverage onBuy

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Aegis CapitalAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (AMRN)

View Comments and Join the Discussion!